Summary The interference by BCG in the induction and expression of a specific antitumoral immune reaction was studied in B6 mice, using the in vivo Winn assay and also active immunization. (2) 
BCG treatment has been shown to induce tumour regression by stimulating cell-mediated immunity (Old et al., 1959; Zbar et al., 1970; Baldwin et al., 1976) . However, numerous studies have established that treatment with high doses of BCG provoked suppressive effects, revealed by inhibition of reactions such as lymphocyte proliferation (Turcotte et al., 1978) , delayed-type hypersensitivity (Watson & Collins, 1980; Florentin et al., 1976) , T cell cytotoxicity developed by mixed lymphocyte culture (Klimpel & Henney, 1978; Davies & Sabbadini, 1977) , or antibody production (Schrier et al., 1980; Kitamura et al., 1976) . Recently, Kendall & Sabbadini (1981) demonstrated that BCG treatment could reduce the production of helper factors (IL-2) capable of stimulating T cell growth, and Klimpel et al. (1979) found that this deficit in IL-2 synthesis by helper T cells could be overcome by the in vitro addition of exogenous IL-2.
We have used the test of adoptive transfer of immunity (Winn, 1961) to study the effects of BCG treatment on the induction of an in vivo T cellmediated specific immune response to tumour antigen. This model has allowed us to study the interactions of BCG at different phases (induction and expression) of the T cell-mediated protective mechanism against a chemically-induced tumour. We have previously demonstrated that B6 mice can be immunized against MC B6-1 tumour cells, a MCA-induced fibrosarcoma, and that immune T cells transferred together with MC B6-1 tumour cells protected the syngeneic host against tumour take. This control of tumour growth in vivo was the result of a complex immunologic mechanism involving cooperation between immunized T lymphocytes and a radio-resistant non T cell of host origin (Poupon et al., 1981) .
In the present study we (i) Immunization with MC B6-1 tumour cells The immunization protocol has been described previously (Poupon et al., 1979) . B6 mice received an initial s.c. injection of 5 x 105 cells obtained from a solid tumour. After 10 days, the resulting tumour was surgically removed. The mice then received challenges of tumour cells at 21-day intervals, and at progressively increasing doses; any tumour take was followed by surgical removal. After the 5th challenge, mice were able to reject a dose of 105 tumour cells and were thus considered immune.
(ii) Immunization with AB2 hybrid tumour cells This immunization protocol, described previously (Payelle et al., 1981) (Julius et al., 1973 bRecorded Day 30. cImmune T spleen cell:tumour cell ratio. dp = 0.05 compared with control group receiving no BCG treatment.
In a second experiment, groups of mice were prepared as described in the protocol under Since the BCG used is a live vaccine, the number of colonies in the spleen of mice injected with 0.05mg became similar to that observed with 1 mg at Day 14, although with a delay of 21-28 days (Figure 1) . Therefore, the application of a small dose such as 0.01 mg BCG twice at a 3 week interval may give rise to a similar bacterial load to that obtained with an inoculum of 1 mg BCG 14 days before. This may lead to the deterioration of the protective effect of cytotoxic T cells against tumour growth. 
Evidence for suppressor cells in BCG-treated mice
In order to demonstrate a suppressive activity mediated by cells present among BCG-SpC, a cell mixture experiment was performed as follows: 107 spleen cells from 0.05 mg or 1 mg BCG-treated mice were added to 4 x 106 immune T cells and 104 tumour cells. This mixture was transferred to syngeneic hosts. The control group consisted of mice receiving N-SpC with immune T cells and tumour cells (Table V) . We observed some degree of protection in the control group (6/18 mice developed tumours). The addition of 107 0.05 mg BCG SpC did not modify the antitumour protection (Table V) . In contrast, the addition of 107 1 mg BCG-SpC resulted in a significant (P<0.02) decreased protection (14/18 mice with tumours). These observations demonstrated that high dose BCG induced suppressor cells that act during the effector stage of the antitumour immune reaction.
A second approach was to determine the effect of these cells on the development of antitumour immunity. We injected i.v. N-SpC or 1 mg BCGSpC into syngeneic B6 hosts which received AB2 hybrid cells 2 h later. Eight days later, splenic T cells from these i.v. injected immunized mice were tested for their protective activity in a Winn assay. Figure 2 illustrates the results obtained after i.v. injection of 1 mg BCG-SpC; either the whole population, or the T-enriched (nylon-wool nonadherent) or T-depleted (anti 0 treated) population.
In these particular experiments, the inhibition of the protective effect by previous injections of BCGSpC was moderate. However, when BCG-SpC were injected after purification we observed an amplified inhibition by the T-enriched population and a loss of inhibition of protection by the T-depleted population (Figure 2) .
In order to determine the phenotype of the T cells responsible for this suppression, T-enriched 1 mg BCG-SpC were treated with anti Lyt 1.2 or anti Lyt 2.2 antibodies +C. The transfer of the whole population as well as the T-enriched BCGSpC actively suppressed the immunization of normal hosts (Figure 3 ). This suppression was found to be mediated by the Lyt 1 subpopulation of T cells since anti Lyt 1 treatment abrogated this suppressive effect, whereas anti Lyt 2 treatment had no effect (Figure 3 ).
Effect of in vivo IL-2 administration on the suppressive activity induced by BCG pretreatment It has previously been assumed that a deficiency in the activity of helper factors might be a major cause of the reduced in vitro cytotoxicity developed by lymphocytes of BCG-treated mice (Kendall & Sabbadini, 1981) . We attempted to test such a hypothesis as an explanation of the inhibitory effects on the antitumoral immune response observed after BCG treatment. In order to 
Discussion
The question addressed was whether BCG interferes with a specific in vivo antitumoral immune reaction and whether this interaction depends upon the dose of BCG and the state of immunization. The expression of active immunity conferred by an AB2 hybrid tumour cell inoculation was eliminated by a previous BCG injection, even at low doses. The mechanism responsible for tumour rejection in this model might be either nonspecific (NK, macrophages) or specific (immune T cells). The method of transferred immunity (Winn assay) circumvented the problem of nonspecific resistance which exists in actively immunized recipients and permitted the study of the effects of BCG on specific immunity mediated by T cells.
We have previously shown (Poupon et al., 1979 (Poupon et al., , 1981 that a specific response could be developed against tumour cells dissociated from MCA fibrosarcoma in B6 mice. Two types of immunizing protocols were used: the first consisted of repeatedly challenging B6 syngeneic mice with live tumour cells, followed by surgical excision of the tumour (Poupon et al., 1979) . The other consisted of a single injection of tumour cells hybridized with an allogeneic cell (Payelle et al., 1981) . These two different types of immunization resulted in an identical immune reaction characterized by a sharp specificity against the tumour cells and the transference of this immune protection only by T cells. Both types of immunization have been used in this study, depending on the question addressed.
Interactions between BCG treatment and the anti MC B6-1 antitumoral reaction were studied at different phases of the development of the immune state. The pretreatment of normal mice by low doses of BCG did not modify the level of the protective effect induced by injection of hybrid tumour cells. In some experiments, such BCG treatment even tended to result in a better response to the tumour antigen. A high dose of BCG (1 mg), however, dramatically inhibited the emergence of an immune response. Such a negative effect has previously been shown by many authors (Davies & Sabbadini, 1977; Florentin et al., 1976; Turcotte et al., 1978; Geffard & Orbach-Arbouys, 1976; Watson & Collins, 1980; Klimpel, 1979) to the progressive development of BCG colonies in the spleen of the treated mice.
In our experiment, two administrations of low doses of BCG at a 22-day interval followed by tumour challenge 10 days later, resulted in an elevated number of bacilli that was more rapidly obtained in the case of a high dose of BCG. Therefore, it is not surprising that similar inhibitory effects were observed in both situations if these effects are linked to the development of BCG colonies. Several possibilities to explain inhibitory effects have to be considered: (i) production of BCG-induced-blocking factors which enhance tumour growth. These factors have been demonstrated in different tumour systems both in mice (Hawrylko, 1977) and rats (Bansal et al., 1973 eliminated the suppressor activity of the BCG-T cell population whereas treatment with anti Lyt 2.2 + C did not affect the suppression. Therefore, the suppression induced by high dose BCG is mediated by Lyt 1 2 -T cells. It was recently demonstrated that antigen nonspecific suppression of cytotoxic T lymphocyte responses to alloantigen is also mediated by a T cell of Ly 1 +2-phenotype (Hathcock & Hodes, 1983) . The presence of suppressor macrophages was shown to be operative, using mainly in vitro systems (Shrier et al., 1980; Klimpel et al., 1979; Wadee et al., 1980) . Suppressor T cells have been implicated in the inhibition of DTH reactions (Nakamura et al., 1982; Kato & Yamamoto, 1982; Watson & Collins, 1980) , lymphoproliferative responses (Florentin et al., 1976) and GVH reactivity (Geffard & OrbachArbouys, 1976) .
Several mechanisms of T cell mediated suppression have bee postulated by the different workers: (i) an increased absorption of helper factors by the suppressor cells ; (ii) an alteration of the kinetics of the interaction between the cytotoxic cells and their targets during the T cell mediated cytotoxicity (Davies & Sabbadini, 1978) ; (iii) an inhibition of the capacity of Lyt 1+ T cells to produce helper factors Kendall & Sabbadini, 1981) , since in vitro addition of exogenous IL-2 completely restored the response. Kendall Combined BCG and IL-2 treatment was followed by delayed tumour growth as compared to BCG given alone. But, since IL-2 given repeatedly to immunized mice abrogated the protection, the interaction between the effects of IL-2 and BCG appears very complex and interpretation of these results is difficult. Our results clearly demonstrate that T suppressor cells of the Ly 1 2-phenotype are responsible, at least partially, for the reduced response induced by high dose BCG. Other mechanisms, beside the intervention of a suppressive activity, have been demonstrated to be implicated in the reduced response of BCG-treated animals: a reduced frequency of CTL precursors (Kendall & Sabbadini, 1981) , an acceleration of the destruction of antigen (Perkins & Makinodan, 1965) , a blockade of the RES (Sabet et al., 1969) .
This work confirms the complex effects of BCG, which may be beneficial or harmful to the immunological control of tumour growth, depending upon its mode of application, and especially on the dosage used. We demonstrated that BCG induces T suppressor cells, active on the afferent and on the efferent arm of the anti-tumour immune response. BCG also stimulates macrophages with antitumour activity. These contradictory activities are important to consider when using BCG in cancer therapy.
